Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 8/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676643 | 0.84 | ALPL (0.46) | ALPLAAK1CA1CA2CA9 | |
| SCHEMBL1502534 | 0.81 | ALPL (0.56) | ALPLAAK1CA1CA2CA9 | |
| SCHEMBL15056968 | 0.80 | AAK1 (0.44) | ALPLAAK1CA1CA2CA9 | |
| SCHEMBL18759846 | 0.80 | ALPL (0.41) | ALPLAAK1DGAT1GSK3AGSK3B | |
| SCHEMBL15956784 | 0.80 | DGAT1 (0.43) | ALPLCA1CA2CA9CA12 | |
| SCHEMBL15559149 | 0.77 | ALPL (0.43) | ALPLAAK1DGAT1GSK3AGSK3B | |
| SCHEMBL9954690 | 0.76 | ALPL (0.57) | ALPLAAK1CA1CA2CA9 | |
| SCHEMBL26673668 | 0.76 | CA1 (0.41) | CA1CA2CA9CA12CA3 | |
| SCHEMBL17450629 | 0.76 | DGAT1 (0.47) | ALPLAAK1DGAT1PDGFRBKDR | |
| SCHEMBL110292 | 0.76 | ALPL (0.45) | ALPLAAK1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4169917-A1 | QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF | Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-110785420-B | Oxazepin derivatives as inhibitors of PI 3-kinase activity | 葛兰素史克知识产权开发有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2014124757-A1 | PYRROLOTRIAZINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-08-21 | — | — | WO | disclosed |
| WO-2014060431-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-04-24 | — | — | WO | disclosed |
| US-8580797-B2 | Compounds | Glaxo Smith Kline Intellectual Property Development Limited (GB) | 2013-11-12 | — | — | US | disclosed |
| EP-2614058-A1 | POLYMORPHS AND SALTS OF N- [5- [4- (5- { [(2R,6S) -2, 6 - DIMETHYL - 4 -MORPHOLINYL]METHYL} - 1, 3 - OXAZOL - 2 - YL) - 1H- INDA ZOL-6-YL]-2- (METHYLOXY) - 3 - PYRIDINYL]METHANESULFONAMIDE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032067-A1 | POLYMORPHS AND SALTS OF N- [5- [4- (5- { [(2R,6S) -2, 6 - DIMETHYL - 4 -MORPHOLINYL] METHYL} - 1, 3 - OXAZOL - 2 - YL) - 1H- INDA ZOL-6-YL] -2- (METHYLOXY) - 3 - PYRIDINYL] METHANESULFONAMIDE | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | ALPL 4135/4885AAK1 315/4885CA1 4748/4885 |
| US-20120046286-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | ALPL 3399/4885AAK1 390/4885CA1 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.